Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(17 sites) United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California Valkyrie Clinical Trials, Los Angeles, California John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey Local Institution - 0045, Columbus, Ohio Local Institution - 0046, Dallas, Texas Local Institution - 0049, Houston, Texas Canada
BC Cancer Vancouver, Vancouver, British Columbia Princess Margaret Cancer Centre, Toronto, Ontario Centre Hospitalier de l'Université de Montréal, Montreal, Quebec Jewish General Hospital, Montreal, Quebec France
Local Institution - 0036, Bordeaux, Aquitaine Local Institution - 0031, Villejuif, Val-de-Marne Local Institution - 0035, Lyon Italy
Local Institution - 0033, Milan Local Institution - 0032, Milan Spain
Local Institution - 0042, Barcelona, Barcelona [Barcelona] Local Institution - 0041, Avda.Pio XII 36,